(Q46913725)

26 December 2017

title

Testosterone replacement therapy and prostate cancer (English)

1 reference

26 December 2017

1 reference

1 reference

1 reference

Abraham Morgentaler

1

1 reference

26 December 2017

publication date

1 November 2007

1 reference

26 December 2017

Urologic Clinics of North America

published in

1 reference

26 December 2017

volume

34

1 reference

26 December 2017

issue

4

1 reference

26 December 2017

page(s)

555-63, vii

1 reference

26 December 2017

STUDIES ON PROSTATIC CANCER

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.002

Risks of testosterone-replacement therapy and recommendations for monitoring

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.002

Managing the Risks of Prostate Disease During Testosterone Replacement Therapy in Older Men: Recommendations for a Standardized Monitoring Plan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.002

Testosterone replacement therapy and the risk of prostate cancer: a perspective view

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.002

Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.002

Response of men with advanced prostatic carcinoma to exogenous administration of testosterone.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.002

Testosterone and prostate cancer: an historical perspective on a modern myth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.002

Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.002

Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.002

Testosterone dose-response relationships in healthy young men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.002

Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.002

Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.002

The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.002

Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.002

Carcinoma of the Prostate in the Absence of Testicular Tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.002

A worse prognosis for men with testicular atrophy at therapeutic orchiectomy for prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.002

The Response of Metastatic Adenocarcinoma of the Prostate to Exogenous Testosterone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.002

Is the flare phenomenon clinically significant?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.002

Prevention of the Transient Adverse Effects of a Gonadotropin-Releasing Hormone Analogue (Buserelin) in Metastatic Prostatic Carcinoma by Administration of an Antiandrogen (Nilutamide)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.002

Prostate-specific antigen: update 2006.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.002

Prostate cancer after exogenous testosterone treatment for impotence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.002

5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.002

The influence of finasteride on the development of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.002

Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.002

Hormones and prostate cancer: what's next?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.002

Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.002

High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.002

Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.002

Prospective study of sex hormone levels and risk of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.002

Occult prostate cancer in men with low serum testosterone levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.002

Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.002

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.002

Is low serum free testosterone a marker for high grade prostate cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.002

High-grade prostate cancer is associated with low serum testosterone levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.002

Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.002

Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.002

Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.002

Testosterone deficiency and prostate cancer: emerging recognition of an important and troubling relationship

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.002

Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.002

Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.002

Testosterone replacement therapy after primary treatment for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.002

Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2007.08.002

10.1016/J.UCL.2007.08.002

7 January 2021

Identifiers

DOI

1 reference

26 December 2017

1 reference

26 December 2017